A rapid, two-step immune reaction may underlie rare cases of heart inflammation seen after Covid mRNA vaccination, Stanford ...

Pfizer's COVID-19 vaccine has become the first in the U.S. to receive full approval from the FDA for people ages 16 and up.

While BioNTech shares are currently trading near their 52-week lows, the Mainz-based biotechnology firm is signaling a significant operational shift. A major ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

On December 14, 2020 I became the first person in the United States to receive the first FDA-approved COVID-19 vaccine. Now, ...

Despite trading near its 52-week low and posting a year-to-date loss of approximately 28%, BioNTech stock is attracting significant attention from major fina ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear ...

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

BioNTech SE ( ($BNTX) ) has provided an update. On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal ...